Consumer Staples Select Sector SPDR Fund vs 22nd Century Group Inc — how do they compare? Consumer Staples Select Sector SPDR Fund trades at $83.37 (market cap $13.50B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 21715.7× 22nd Century Group Inc's market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Consumer Staples Select Sector SPDR Fund for 72 Days and 22nd Century Group Inc for 32 Days on average.
| XLP | XXII | |
|---|---|---|
Market Cap | $13.50B | $621.67K |
Volume | 14,599,953 | 45,625 |
52-Week High | $90.00 | $483.00 |
52-Week Low | $75.61 | $0.80 |
Typical Hold Time | 72 Days | 32 Days |
Sector | — | Consumer Staples |
Enterprise Value | — | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
XLP trades at $83.43, up 2.12% with strong bullish technical signals from moving averages and oscillators. The ETF shows defensive sector strength, gaining 6.6% year-to-date while consumer discretionary lags. Analyst consensus is unanimously bullish with 100% buy ratings. Recent dividend declaration of $0.54 payable in September 2026 adds income appeal.
Outlook remains positive given consumer staples' defensive characteristics amid economic uncertainty. Key opportunities include sector outperformance and dividend yield, while risks center on interest rate sensitivity and potential consumer spending slowdown. The ETF's low 0.08% expense ratio provides cost advantage over peers.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →